{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:51:26Z","timestamp":1770918686394,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd005133.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T00:00:00Z","timestamp":1362009600000}}],"reference-count":199,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005133.pub3","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T06:02:01Z","timestamp":1361599321000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients"],"prefix":"10.1002","author":[{"given":"Daniel S","family":"Owers","sequence":"first","affiliation":[{"name":"Australian National University; Australian National University Medical School; Canberra ACT Australia 0200"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Kable","sequence":"additional","affiliation":[{"name":"Westmead Hospital; Department of Renal Medicine and Transplantation; Darcy Rd Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.V81118","article-title":"Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy","volume":"8","author":"Brennan","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1-2","key":"10.1002\/14651858.CD005133.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0041-1345(96)00143-1","article-title":"Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients","volume":"29","author":"Brennan","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1086\/315477","article-title":"The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir","volume":"18","author":"Brennan","year":"2000","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/TP.0b013e31817889e4","article-title":"Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation","volume":"86","author":"Gerna","year":"2008","journal-title":"Transplantation"},{"issue":"7-8","key":"10.1002\/14651858.CD005133.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/S0041-1345(01)02558-1","article-title":"Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation","volume":"33","author":"Jung","year":"2001","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0006|cit6","unstructured":"Offermann G Jung C Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation [abstract no: 1094] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"issue":"Oct","key":"10.1002\/14651858.CD005133.pub3-BIB0007|cit7","first-page":"23A","article-title":"Preemptive vs prophylactic valganciclovir for CMV in renal transplantation: early results from a randomized, prospective trial. [abstract]","volume":"15","author":"Brennan","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/TP.0b013e3181e81afc","article-title":"Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes","volume":"90","author":"Spinner","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005133.pub3-BIB0011|cit11","first-page":"111A","article-title":"Influence of prophylactic compared with early ganciclovir treatment on graft survival in renal allograft recipients. [abstract]","volume":"17","author":"Radermacher","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD005133.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00007890-200110150-00025","article-title":"Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective double-blind, placebo-controlled study","volume":"72","author":"Koetz","year":"2001","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD005133.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1086\/339449","article-title":"Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial","volume":"185","author":"Paya","year":"2002","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005133.pub3-BIB0014|cit14","first-page":"511","article-title":"A prospective, randomized controlled trial comparing oral ganciclovir with weekly-monitored CMV-antigenemia in renal transplant patients with a high-risk for CMV infection. [abstract]","volume":"3","author":"Queiroga","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Rayes N Seehofer D Oettle H Schmidt CA Neuhaus R Steinmuller T Prospective randomised trial to assess the value of preemptive oral therapy for CMV-infection after OLT. [abstract] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome, Italy 2000","DOI":"10.1016\/S0168-8278(01)80877-1"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00007890-200109150-00024","article-title":"Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation","volume":"72","author":"Rayes","year":"2001","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0017|cit17","article-title":"Improved long-term renal allograft survival in preemptive valganciclovir therapy compared to valacyclovir prophylaxis for cytomegalovirus: results of randomized controlled trial [abstract no: O-145]","volume":"24","author":"Reischig","year":"2011","journal-title":"Transplant International"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1681\/ASN.2012010100","article-title":"Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for the prevention of cytomegalovirus in renal transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0020|cit20","first-page":"185","article-title":"Valacyclovir prophylaxis for cytomegalovirus is associated with reduced risk of acute renal allograft rejection compared to preemptive valganciclovir therapy. [abstract]","volume":"20","author":"Reischig","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0021|cit21","first-page":"279","article-title":"The economic impact of different regimens to prevent cytomegalovirus disease in renal transplant recipients. [abstract]","volume":"22","author":"Reischig","year":"2009","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0022|cit22","unstructured":"Reischig T Nemcova J Vanecek T Jindra P Hes O Bouda M Cytomegalovirus DNA in renal allograft biopsy specimens in transplant recipients managed by preemptive valganciclovir therapy or valacyclovir prophylaxis [abstract no: SA708] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3851\/IMP1485","article-title":"Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients","volume":"15","author":"Reischig","year":"2010","journal-title":"Antiviral Therapy"},{"issue":"2S","key":"10.1002\/14651858.CD005133.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.tp.0000332482.73775.a2","article-title":"Preemptive valganciclovir therapy is not associated with increase in cytomegalovirus (CMV) DNA in renal allograft biopsy specimens compared with valacyclovir prophylaxis. [abstract]","volume":"86","author":"Reischig","year":"2008","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0025|cit25","first-page":"324","article-title":"Cytomegalovirus infection in the graft: Results of a randomised study comparing valacyclovir prophylaxis and preemptive treatment after renal transplantation [abstract]","volume":"33","author":"Reischig","year":"2010","journal-title":"Kidney & Blood Pressure Research"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0026|cit26","first-page":"324","article-title":"Cytomegalovirus infection in the graft: Results of a randomised study comparing valacyclovir prophylaxis and preemptive treatment after renal transplantation [abstract]","volume":"33","author":"Reischig","year":"2010","journal-title":"Kidney & Blood Pressure Research"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/ndt\/gfg302","article-title":"Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study","volume":"18","author":"Sagedal","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7326\/0003-4819-120-5-199403010-00004","article-title":"High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients","volume":"120","author":"Singh","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00007890-200009150-00002","article-title":"Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients","volume":"70","author":"Singh","year":"2000","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/00007890-199806270-00461","article-title":"CMV antigenemia directed preemptive prophylaxis with oral ganciclovir for the prevention of CMV disease in liver transplant recipients: a prospective, randomised, controlled trial. [abstract]","volume":"65","author":"Singh","year":"1998","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00007890-201007272-00359","article-title":"CMV valganciclovir prophylaxis versus preemptive therapy after renal transplantation: one year results of a randomized clinical trial. [abstract]","volume":"90","author":"Witzke","year":"2010","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0033|cit33","first-page":"1928","article-title":"Indication of ganciclovir treatment during early cytomegalovirus (cmv) viremia in CMV seropositive recipients. a longitudinal study of CMV pp65 antigenemia (Ag) assay. [abstract]","volume":"7","author":"Yang","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013379","article-title":"Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients","volume":"18","author":"Yang","year":"1998","journal-title":"American Journal of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0035|cit35","first-page":"1929","article-title":"Oral ganciclovir (CytoveneR) effectively prevents cytomegalovirus (CMV) infection in renal transplant patients [abstract]","volume":"7","author":"Ahsan","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-0012.1997.tb01057.x","article-title":"Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients","volume":"11","author":"Ahsan","year":"1997","journal-title":"Clinical Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0037|cit37","first-page":"S70","article-title":"Oral ganciclovir is effective in preventing CMV infection in renal transplant recipients. [abstract]","volume":"3","author":"Ahsan","year":"1997","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0041-1345(98)00283-8","article-title":"Oral ganciclovir in the prevention of cytomegalovirus infection in post kidney transplant \"CMV at risk\" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)","volume":"30","author":"Ahsan","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1399-0012.2000.140105.x","article-title":"Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis","volume":"14","author":"Arbo","year":"2000","journal-title":"Clinical Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-199707150-00013","article-title":"Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir","volume":"64","author":"Badley","year":"1997","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/jmv.1890410524","article-title":"Solid organ transplantation: results and implications of acyclovir use in liver transplants","volume":"Suppl 1","author":"Paya","year":"1993","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0044|cit42","first-page":"88","article-title":"Prevention of cytomegalovirus disease in renal allograft recipients","volume":"80","author":"Balfour","year":"1991","journal-title":"Scandinavian Journal of Infectious Diseases - Supplement"},{"issue":"21","key":"10.1002\/14651858.CD005133.pub3-BIB0042|cit43","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM198905253202105","article-title":"A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts","volume":"320","author":"Balfour","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0043|cit44","first-page":"17","article-title":"Prevention of cytomegalovirus disease with oral acyclovir","volume":"23","author":"Balfour","year":"1991","journal-title":"Transplantation Proceedings"},{"issue":"1A","key":"10.1002\/14651858.CD005133.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0002-9343(82)90099-7","article-title":"Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution","volume":"73","author":"Balfour Jr","year":"1982","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.35.5.938","article-title":"Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients","volume":"35","author":"Fletcher","year":"1991","journal-title":"Antimicrobial Agents & Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1034\/j.1399-3062.1999.010202.x","article-title":"High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients","volume":"1","author":"Barkholt","year":"1999","journal-title":"Transplant Infectious Disease"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00007890-199712270-00036","article-title":"Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients","volume":"64","author":"Brennan","year":"1997","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0049|cit49","unstructured":"Brennan DC Garlock KA Singer GG Schnizler MA Lippmann BJ Buller RS Prophylactic oral ganciclovir prevents cytomegalovirus infection and disease in renal transplant recipients. [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (IL) 1997 87"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0050|cit50","first-page":"S197","article-title":"Prophylactic oral ganciclovir prevents cytomegalovirus disease in renal transplant recipients. [abstract]","volume":"3","author":"Brennan","year":"1997","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1086\/315477","article-title":"The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir","volume":"181","author":"Brennan","year":"2000","journal-title":"Journal of Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0052|cit52","first-page":"1941","article-title":"Prophylactic oral ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients. [abstract]","volume":"7","author":"Singer","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jmv.1890400103","article-title":"Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults","volume":"40","author":"Cohen","year":"1993","journal-title":"Journal of Medical Virology"},{"issue":"11","key":"10.1002\/14651858.CD005133.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archsurg.1995.01430110075014","article-title":"Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients","volume":"130","author":"Conti","year":"1995","journal-title":"Archives of Surgery"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0055|cit55","unstructured":"Denny RR Asolati M Dunn DL Sutherland D Gillingham KJ Matas AJ Potent immunosuppression, CMV prophylaxis, and CMV risk. [abstract] Transplant 2002 - American Transplant Congress; 2002 Apr 26- May 1; Washington DC 2002"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0056|cit56","unstructured":"Devolder I The influence of intensive education and coaching on compliance for oral ganciclovir in the prophylaxis of CMCV: an open randomised trial http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00566072"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/106002809603001215","article-title":"Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients","volume":"30","author":"Dickinson","year":"1996","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/ajrccm.150.1.8025741","article-title":"A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation","volume":"150","author":"Duncan","year":"1994","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1053-2498(01)00399-0","article-title":"Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial","volume":"21","author":"Egan","year":"2002","journal-title":"Journal of Heart & Lung Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005133.pub3-BIB0060|cit60","first-page":"293","article-title":"CMV infections in primary simultaneous pancreas-kidney (SPK) transplantation: results at 1 year of a large multicenter trial. [abstract]","volume":"3","author":"Kuypers","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Langrehr J Malaise J Tyden G CMV infections in primary simultaneous pancreas-kidney (SPK) transplantation: results at 1 year of a large multicenter trial. [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002","DOI":"10.1016\/S0041-1345(02)03120-2"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005133.pub3-BIB0062|cit62","first-page":"803","article-title":"CMV infections in primary simultaneous pancreas-kidney (SPK) transplantation: results at 1 year of a large multicenter trial. [abstract]","volume":"18","author":"Malaise","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1016\/j.transproceed.2005.05.021","article-title":"Cytomegalovirus infection in simultaneous pancreas-kidney transplantation","volume":"37","author":"Malaise","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/ndt\/gfh1079","article-title":"Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation","volume":"20","author":"Ricart","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD005133.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0012.1997.tb00847.x","article-title":"Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group","volume":"11","author":"Falagas","year":"1997","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0066|cit66","unstructured":"Falagas ME Snydman DR Werner B Griffith J Ruthazer R Rohrer R Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (IL) 1997 148"},{"issue":"1 Pt 3","key":"10.1002\/14651858.CD005133.pub3-BIB0067|cit67","first-page":"3107","article-title":"Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation","volume":"21","author":"Fehir","year":"1989","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Ferreira A Felipe CR Motegi SA Hosaka BA Tamura MK Kamura LA Relationship between immunosuppression and subsequent development of CMV disease. [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego, (CA) 2004","DOI":"10.1097\/00007890-200407271-00870"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00007890-200002150-00014","article-title":"Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients","volume":"69","author":"Fishman","year":"2000","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1097\/00007890-199812270-00019","article-title":"A randomized prospective controlled trial of oral acyclovir versus oral, ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"66","author":"Flechner","year":"1998","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1097\/00007890-199806270-00758","article-title":"A randomized prospective trial of oral acyclovir vs oral ganciclovir for CMV prophylaxis in high risk kidney transplant recipients. [abstract]","volume":"65","author":"Flechner","year":"1998","journal-title":"Transplantation"},{"issue":"9093","key":"10.1002\/14651858.CD005133.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"issue":"2 bis","key":"10.1002\/14651858.CD005133.pub3-BIB0073|cit73","first-page":"A157","article-title":"A randomized double blind versus placebo multicenter study of efficacy and tolerance of oral ganciclovir in the prevention of cytomegalovirus disease in hepatic transplanted patients","volume":"21","author":"Saliba","year":"1997","journal-title":"Gastroenterologie Clinique et Biologique"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1432-2277.1997.tb00725.x","article-title":"Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients","volume":"10","author":"Gavalda","year":"1997","journal-title":"Transplant International"},{"issue":"7","key":"10.1002\/14651858.CD005133.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/01.TP.0000057239.32192.B9","article-title":"Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial","volume":"75","author":"Gerna","year":"2003","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/135965350701200108","article-title":"Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study","volume":"12","author":"Gerna","year":"2007","journal-title":"Antiviral Therapy"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/516139","article-title":"Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein- Barr virus disease after liver transplantation in children","volume":"25","author":"Green","year":"1997","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0078|cit78","first-page":"173","article-title":"Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis","volume":"26","author":"Green","year":"1994","journal-title":"Transplantation Proceedings"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0079|cit79","first-page":"466","article-title":"Are the risks of viral infections increased in kidney transplant patients receiving triple-drug therapy?","volume":"20","author":"Greger","year":"1988","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0080|cit80","unstructured":"Griffiths PD Determining a viral load threshold for treating cytomegalovirus (CMV) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00947141"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/infdis\/157.1.187","article-title":"Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia","volume":"157","author":"Hecht","year":"1988","journal-title":"Journal of Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0082|cit82","first-page":"913","article-title":"Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation","volume":"17","author":"Hertz","year":"1988","journal-title":"Journal of Heart & Lung Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/0003-4819-123-1-199507010-00002","article-title":"Preemptive ganciclovir therapy to prevent cytomegalovirus disease, in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial","volume":"123","author":"Hibberd","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005133.pub3-BIB0084|cit84","first-page":"126","article-title":"Cost-effectiveness model to evaluate 200-day vs 100-day valganciclovir (Valcyte\u00ae) prophylaxis to reduce CMV disease incidence post-transplant. [abstract]","volume":"10","author":"Blumberg","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/TP.0b013e3181fdd9d2","article-title":"Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis","volume":"90","author":"Chou","year":"2010","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005133.pub3-BIB0086|cit86","first-page":"208","article-title":"The IMPACT Study: genotypic analysis of cytomegalovirus UL54 and UL97 genes derived from patients receiving 100 or 200 days of valganciclovir (Valcyte\u00ae) prophylaxis. [abstract]","volume":"10","author":"Elston","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-6143.2010.03370.x","article-title":"Response to questions regarding the design and results of the IMPACT trial","volume":"11","author":"Humar","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005133.pub3-BIB0088|cit88","first-page":"143","article-title":"Long term results of the IMPACT study: 200 vs 100 days of valganciclovir prophylaxis in kidney transplant recipients. [abstract]","volume":"10","author":"Humar","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0090|cit90","first-page":"248","article-title":"The Impact Study: Valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease. [abstract]","volume":"9","author":"Humar","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-6143.2010.03370.x","article-title":"Response to questions regarding the design and results of the IMPACT trial","volume":"11","author":"Humar","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-6143.2010.03342.x","article-title":"IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis","volume":"11","author":"Kalil","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-6143.2010.03342.x","article-title":"IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis","volume":"11","author":"Kalil","year":"2011","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/TP.0b013e3182000042","article-title":"Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days","volume":"90","author":"Welker","year":"2010","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/lt.500020507","article-title":"Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection","volume":"2","author":"Jurim","year":"1996","journal-title":"Liver Transplantation & Surgery"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00007890-200002150-00008","article-title":"The economic impact of cytomegalovirus infection after liver transplantation","volume":"69","author":"Kim","year":"2000","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0166-3542(98)00050-3","article-title":"Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients","volume":"40","author":"King","year":"1999","journal-title":"Antiviral Research"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1681\/ASN.V72325","article-title":"Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients","volume":"7","author":"Kletzmayr","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0100|cit100","unstructured":"Kletzmayr J Kotzmann H Popow-Kraupp T Kovarik J Klauser R Oral acyclovir in prevention of CMV disease in high-risk renal transplant recipients. [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 375"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/00007890-200010270-00008","article-title":"Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients","volume":"70","author":"Kletzmayr","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0102|cit102","first-page":"2448","article-title":"Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients","volume":"27","author":"Leray","year":"1995","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD005133.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00007890-200011270-00012","article-title":"Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation","volume":"70","author":"Legendre","year":"2000","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/00007890-199806270-00084","article-title":"Valaciclovir reduces the incidence of cytomegalovirus disease and acute graft rejection in CMV-seronegative recipients of a seropositive cadaveric renal allograft. [abstract]","volume":"65","author":"Lowance","year":"1998","journal-title":"Transplantation"},{"issue":"19","key":"10.1002\/14651858.CD005133.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group","volume":"340","author":"Lowance","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0106|cit106","unstructured":"Squifflet J Mendez R Valaciclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive renal allograft recipients. [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (IL) 1997 87"},{"issue":"11","key":"10.1002\/14651858.CD005133.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1128\/AAC.37.11.2490","article-title":"Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies","volume":"37","author":"Lumbreras","year":"1993","journal-title":"Antimicrobial Agents & Chemotherapy"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD005133.pub3-BIB0108|cit108","first-page":"1355","article-title":"Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir","volume":"23","author":"MacDonald","year":"1991","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0109|cit109","first-page":"32","article-title":"A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"14","author":"Macdonald","year":"1995","journal-title":"Journal of Heart & Lung Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD005133.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archinte.1980.00330220027012","article-title":"A trial of vidarabine for cytomegalovirus infection in renal transplant patients","volume":"140","author":"Marker","year":"1980","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/383040","article-title":"A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients","volume":"189","author":"Mattes","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"18","key":"10.1002\/14651858.CD005133.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"326","author":"Merigan","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0113|cit113","first-page":"382","article-title":"Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients","volume":"17","author":"Moreno","year":"1999","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/S0041-1345(98)01361-X","article-title":"Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients","volume":"30","author":"Mullen","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005133.pub3-BIB0115|cit115","first-page":"695A","article-title":"Cost comparison of two approaches to the management of CMV infection in renal transplant recipients. [abstract]","volume":"8","author":"Murray","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0116|cit116","first-page":"1935","article-title":"Viral prophylaxis in hepatic transplantation: Preliminary report of a randomized trial of acyclovir and ganciclovir","volume":"25","author":"Nakazato","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.healun.2011.01.111","article-title":"Reduced lifetime incidence of cytomegalovirus with extended prophylaxis: Long-term follow up from a randomized controlled trial. [abstract]","volume":"30","author":"Finlen Copeland","year":"2011","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1086\/382753","article-title":"Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients","volume":"189","author":"Boivin","year":"2004","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005133.pub3-BIB0120|cit120","first-page":"391","article-title":"Risk factors for cytomegalovirus (CMV) disease: results from a multicenter randomized trial of valganciclovir (VGC). [abstract]","volume":"3","author":"Freeman","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1600-6143.2005.00797.x","article-title":"Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+\/R- transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005133.pub3-BIB0123|cit123","first-page":"299","article-title":"Valganciclovir for prevention of CMV disease: 12 month follow up of a randomized trial of 364 D+\/R- transplant recipients. [abstract]","volume":"3","author":"Pescovitz","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"issue":"11","key":"10.1002\/14651858.CD005133.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD005133.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"40","key":"10.1002\/14651858.CD005133.pub3-BIB0127|cit127","first-page":"2022","article-title":"Influence of HLA compatibility on cytomegalovirus infection in kidney transplantation","volume":"20","author":"Pouteil-Noble","year":"1991","journal-title":"Presse Medicale"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0128|cit128","first-page":"2811","article-title":"Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: A randomized, controlled trial","volume":"28","author":"Pouteil-Noble","year":"1996","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0129|cit129","unstructured":"Pouteil-Noble C Megas F Chapuis F Colul C Bosshard S Hadj-Aissa A Is CMV prophylaxis by ganciclovir-high dose acyclovir worthwhile in renal transplantation? A randomized, controlled, clinical and economical trial. [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 343"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0130|cit130","first-page":"294","article-title":"Prospective study of preemptive prophylaxis strategy combined with recipient\u2019 risk-factors to prevent CMV disease after kidney transplantation","volume":"29","author":"Qiu","year":"2008","journal-title":"China Journal of Organ Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Reischig T Bouda M Opatrny K Jr Treska V Jindra P Svecova M Oral ganciclovir versus valacyclovir for prophylaxis of cytomegalovirus disease in renal transplant recipients. [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002","DOI":"10.1007\/s00147-002-0475-0"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.TP.0000150024.01672.CA","article-title":"Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection","volume":"79","author":"Reischig","year":"2005","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005133.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00007890-200407271-01301","article-title":"Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection: a randomized comparison with oral ganciclovir and deferred therapy. [abstract]","volume":"78","author":"Reischig","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD005133.pub3-BIB0134|cit134","first-page":"493","article-title":"Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection: a randomized comparison of oral ganciclovir and valacyclovir. [abstract]","volume":"4","author":"Reischig","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2006.01.015","article-title":"The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection","volume":"36","author":"Reischig","year":"2006 Jun","journal-title":"Journal of Clinical Virology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD005133.pub3-BIB0136|cit136","first-page":"382","article-title":"The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft infection. [abstract]","volume":"5","author":"Reischig","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0137|cit137","first-page":"279","article-title":"The economic impact of different regimens to prevent cytomegalovirus disease in renal transplant recipients. [abstract]","volume":"22","author":"Reischig","year":"2009","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000087129","article-title":"Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"28","author":"Reischig","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1432-2277.2002.tb00120.x","article-title":"A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation","volume":"15","author":"Reischig","year":"2002","journal-title":"Transplant International"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0140|cit140","first-page":"858","article-title":"Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients","volume":"8","author":"Rondeau","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005133.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/tri.1992.5.s1.30","article-title":"Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors","volume":"5","author":"Rondeau","year":"1992","journal-title":"Transplant International"},{"issue":"41","key":"10.1002\/14651858.CD005133.pub3-BIB0142|cit142","first-page":"1979","article-title":"Prophylaxis of cytomegalovirus infections with ganciclovir in kidney transplant recipients","volume":"21","author":"Rondeau","year":"1992","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1432-2277.1994.tb01384.x","article-title":"Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients","volume":"7 Suppl 1","author":"Rostaing","year":"1994","journal-title":"Transplant International"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3062.2000.020303.x","article-title":"Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis","volume":"2","author":"Rubin","year":"2000","journal-title":"Transplant Infectious Disease"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD005133.pub3-BIB0145|cit145","first-page":"1444","article-title":"Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients","volume":"25","author":"Saliba","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00044011-200019050-00007","article-title":"A 3-year follow-up of pre-emptive vs deferred treatment of cytomegalovirus disease in renal transplantation","volume":"19","author":"Schnitzler","year":"2000","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0147|cit147","first-page":"964","article-title":"Efficacy of cytomegalovirus prophylaxis in renal retransplantation","volume":"27","author":"Singh","year":"1995","journal-title":"Transplantation Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10096-002-0801-6","article-title":"Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?","volume":"21","author":"Singh","year":"2002","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00007890-199901270-00023","article-title":"Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation","volume":"67","author":"Speich","year":"1999","journal-title":"Transplantation"},{"issue":"18","key":"10.1002\/14651858.CD005133.pub3-BIB0150|cit150","first-page":"1695","article-title":"Preemptive therapy for prevention and treatment of cytomegalovirus disease after renal transplantation","volume":"26","author":"Tian","year":"2005","journal-title":"Journal of the Fourth Military Medical University"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00007890-200208270-00026","article-title":"The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation","volume":"74","author":"Tong","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0152|cit152","first-page":"213","article-title":"Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients","volume":"70","author":"Tong","year":"2000","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1097\/00007890-199812270-00036","article-title":"Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy","volume":"66","author":"Turgeon","year":"1998","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.100.1.61","article-title":"Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study","volume":"100","author":"Valantine","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","article-title":"Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients","volume":"10","author":"Asberg","year":"2010","journal-title":"American Journal of Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005133.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.tp.0000332158.73633.ff","article-title":"Oral valganciclovir and intravenous ganciclovir results in comparable long-term outcomes in transplant recipients with CMV disease: the VICTOR study. [abstract]","volume":"86","author":"Asberg","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antiviral Therapy"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-6143.2008.02501.x","article-title":"An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes","volume":"9","author":"Humar","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005133.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.tp.0000332156.88880.c6","article-title":"A prospective study of viral genetic polymorphisms in CMV glycoprotein B and their association with clinical and virologic outcomes in patients with CMV disease: results from the VICTOR Study. [abstract]","volume":"86","author":"Manual","year":"2008","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1086\/605633","article-title":"Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease","volume":"49","author":"Manuel","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005133.pub3-BIB0163|cit163","first-page":"183","article-title":"Management of post transplant CMV disease: lessons learned from the VICTOR trial. [abstract]","volume":"8","author":"Pescovitz","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0164|cit164","unstructured":"Villano SA Maribavir versus oral ganciclovir for the prevention of cytomegalovirus (CMV) disease in liver transplant recipients http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00497796"},{"issue":"8967","key":"10.1002\/14651858.CD005133.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(95)92110-9","article-title":"Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients","volume":"346","author":"Winston","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.TP.0000040601.60276.96","article-title":"Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients","volume":"75","author":"Winston","year":"2003","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.TP.0000093463.86584.AC","article-title":"Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors","volume":"77","author":"Winston","year":"2004","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD005133.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0041-1345(98)01930-7","article-title":"A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients","volume":"31","author":"Yang","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD005133.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jcv.2011.05.012","article-title":"Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients","volume":"51","author":"Scott","year":"2011","journal-title":"Journal of Clinical Virology"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0170|cit170","unstructured":"Hoffmann-La Roche A study of Valcyte (valganciclovir)\u00a0CMV\u00a0prophylaxis after renal\u00a0transplantation http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00372229"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0171|cit171","unstructured":"Potena L Grigioni F Prevention of\u00a0Transplant\u00a0Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (PROTECT) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00966836"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0172|cit172","unstructured":"Singh N Prophylaxis Versus Preemptive Therapy for the Prevention of\u00a0CMV\u00a0in Liver\u00a0Transplant\u00a0Recipients (CAPSIL) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01552369"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/lt.21280","article-title":"Delayed-onset primary cytomegalovirus disease after liver transplantation","volume":"13","author":"Arthurs","year":"2007","journal-title":"Liver Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0175|cit175","volume-title":"Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation","author":"British Transplantation Society","year":"2011"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0176|cit176","unstructured":"Pillmore H Pre-emptive treatment of cytomegalovirus http:\/\/www.cari.org.au\/TRANS_cmv_published\/Pre-emptive_treatment_CMV_Oct_2011.pdf"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD005133.pub3-BIB0177|cit177","first-page":"52","article-title":"Section III: The transplant recipient from initial transplant hospitalization to 1 year post transplant","volume":"15","author":"European Best Practice Guidelines Expert Group on Renal Transplantation","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/rmv.310","article-title":"Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation","volume":"11","author":"Emery","year":"2001","journal-title":"Reviews in Medical Virology"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","article-title":"Cytomegalovirus in transplantation - challenging the status quo","volume":"21","author":"Fishman","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/rmv.309","article-title":"Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation","volume":"11","author":"Hart","year":"2001","journal-title":"Reviews in Medical Virology"},{"issue":"7499","key":"10.1002\/14651858.CD005133.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/bmj.38413.576713.AE","article-title":"Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals","volume":"330","author":"Hewitt","year":"2005","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD005133.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0184|cit184","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9477","key":"10.1002\/14651858.CD005133.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD005133.pub3-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9 Suppl 4","author":"Humar","year":"2009","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005133.pub3-BIB0188|cit188","first-page":"S44","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9 Suppl 3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2010.141","article-title":"Management of cytomegalovirus infection in solid organ transplantation","volume":"6","author":"Kotton","year":"2010","journal-title":"Nature Reviews Nephrology"},{"issue":"9230","key":"10.1002\/14651858.CD005133.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD005133.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.tp.0000280538.30629.99","article-title":"Antiviral therapies for cytomegalovirus in solid-organ transplantation","volume":"84","author":"Pescovitz","year":"2007","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD005133.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/00007890-199806270-00461","article-title":"CMV antigenemia directed preemptive prophylaxis with oral ganciclovir for the prevention of CMV disease in liver transplant recipients: a prospective, randomised, controlled trial. [abstract]","volume":"65","author":"Singh","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD005133.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0041-1345(98)00547-8","article-title":"Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease","volume":"30","author":"Waiser","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"9","key":"10.1002\/14651858.CD005133.pub3-BIB0195|cit195","first-page":"1928","article-title":"Indication of ganciclovir treatment during early cytomegalovirus (CMV) viremia in CMV seropositive recipients. a longitudinal study of CMV pp65 antigenemia (Ag) assay. [abstract]","volume":"7","author":"Yang","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005133.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1399-3062.2011.00652.x","article-title":"Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Zhang","year":"2011","journal-title":"Transplant Infectious Disease"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0197|cit197","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005133","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","author":"Strippoli","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005133.pub3-BIB0198|cit198","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005133.pub2","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005133.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.tp.0000183970.71366.da","article-title":"Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"81","author":"Strippoli","year":"2006","journal-title":"Transplantation"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005133.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005133.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:01:36Z","timestamp":1745964096000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005133.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":199,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005133.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}